Altered Striatocerebellar Metabolism and Systemic Inflammation in Parkinson’s Disease

Table 1

Demographic data and inflammatory markers of PD patients and controls.

Parameters	PD patients ()	Controls ()	value
Age (year) (mean ± SD)	59.80 ± 9.24	57.00 ± 9.58	0.239
Sex (M, F)	22, 11	17, 13	0.423
UPDRS I	3.50 (2.00, 6.25)
UPDRS II	10.00 (6.00, 15.25)
UPDRS III	21.50 (17.00, 34.50)
UPDRS total scores	34.00 (25.75, 54.50)
Modified HY-stage (maximum stage is 5)	2.50 (1.00, 3.00)
SE-ADL (minimum score 0 suggests presence of only vegetative function)	80 (70, 90)
MMSE	24 (21, 28)	27 (26, 29)
Inflammation parameters
Total apoptotic leukocytes (%)	1.26 (0.79, 2.09)	0.77 (0.46, 0.95)
Apoptotic neutrophils (%)	0.81 (0.56, 1.47)	0.48 (0.26, 0.60)
Apoptotic monocytes (%)^#	3.85 (2.28, 7.62)	1.79 (1.27, 3.35)
Apoptotic lymphocytes (%)	0.55 (0.35, 0.76)	0.32 (0.21, 0.50)
Nuclear DNA (ng/mL)	55.70 (27.20, 72.50)	25.45 (20.35, 33.68)
Mitochondria DNA (ng/mL)	36.00 (28.40, 43.00)	23.80 (26.50, 39.70)

PD: Parkinson’s disease; UPDRS: Unified Parkinson’s Disease Rating Scale; modified HY-stage: modified Hoehn Yahr staging scale; SE-ADL: Schwab and England Activities of Daily Living Scale; MMSE: Mini-Mental State Examination.
, PD patients versus controls.
Median (IQR): IQR: interquartile range.